BB&T Investment Services Inc. acquired a new stake in West Pharmaceutical Services, Inc. (NYSE:WST) during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 4,324 shares of the medical instruments supplier’s stock, valued at approximately $417,000.

Several other large investors also recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its holdings in shares of West Pharmaceutical Services by 1.8% in the second quarter. Vanguard Group Inc. now owns 6,555,351 shares of the medical instruments supplier’s stock valued at $619,612,000 after purchasing an additional 114,507 shares during the last quarter. BlackRock Inc. increased its holdings in shares of West Pharmaceutical Services by 7.1% in the second quarter. BlackRock Inc. now owns 6,217,894 shares of the medical instruments supplier’s stock valued at $587,715,000 after purchasing an additional 412,858 shares during the last quarter. State Street Corp increased its holdings in shares of West Pharmaceutical Services by 2.8% in the second quarter. State Street Corp now owns 2,511,108 shares of the medical instruments supplier’s stock valued at $237,351,000 after purchasing an additional 67,937 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in shares of West Pharmaceutical Services by 10.1% in the second quarter. Goldman Sachs Group Inc. now owns 935,685 shares of the medical instruments supplier’s stock valued at $88,441,000 after acquiring an additional 86,022 shares during the period. Finally, Hermes Investment Management Ltd. boosted its position in shares of West Pharmaceutical Services by 3.3% in the third quarter. Hermes Investment Management Ltd. now owns 908,655 shares of the medical instruments supplier’s stock valued at $87,467,000 after acquiring an additional 28,955 shares during the period. Hedge funds and other institutional investors own 93.28% of the company’s stock.

Shares of West Pharmaceutical Services, Inc. (NYSE WST) traded up $0.28 during trading on Tuesday, hitting $99.39. 344,600 shares of the stock were exchanged, compared to its average volume of 363,565. The company has a market capitalization of $7,359.21, a PE ratio of 42.72, a PEG ratio of 2.11 and a beta of 1.11. West Pharmaceutical Services, Inc. has a 52 week low of $77.97 and a 52 week high of $103.36. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.87 and a current ratio of 2.59.

West Pharmaceutical Services (NYSE:WST) last announced its earnings results on Thursday, October 26th. The medical instruments supplier reported $0.67 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.53 by $0.14. The company had revenue of $398.20 million during the quarter, compared to analysts’ expectations of $386.02 million. West Pharmaceutical Services had a net margin of 12.12% and a return on equity of 14.47%. West Pharmaceutical Services’s quarterly revenue was up 5.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.53 earnings per share. equities analysts anticipate that West Pharmaceutical Services, Inc. will post 2.76 EPS for the current year.

A number of equities research analysts have recently issued reports on the stock. Stephens assumed coverage on shares of West Pharmaceutical Services in a research report on Tuesday, October 3rd. They issued an “equal weight” rating and a $99.00 target price for the company. Jefferies Group raised shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating and boosted their target price for the company from $96.00 to $115.00 in a research report on Friday, September 15th. Wells Fargo & Company boosted their target price on shares of West Pharmaceutical Services from $105.00 to $112.00 and gave the company an “outperform” rating in a research report on Friday, October 27th. Zacks Investment Research raised shares of West Pharmaceutical Services from a “sell” rating to a “hold” rating in a research report on Wednesday, September 27th. Finally, Bank of America cut shares of West Pharmaceutical Services from a “buy” rating to a “neutral” rating and set a $98.00 target price for the company. in a research report on Tuesday, October 17th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company. West Pharmaceutical Services currently has a consensus rating of “Hold” and an average target price of $106.00.

TRADEMARK VIOLATION NOTICE: “BB&T Investment Services Inc. Acquires New Holdings in West Pharmaceutical Services, Inc. (WST)” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another site, it was stolen and reposted in violation of US & international copyright law. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/12/05/bbt-investment-services-inc-acquires-new-holdings-in-west-pharmaceutical-services-inc-wst.html.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST).

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services Inc. and related companies with MarketBeat.com's FREE daily email newsletter.